US · Healthcare · Biotechnology
EPS came in at -0.14 against a street estimate of -0.20 — a beat of 30.0%.
Analysts rate Abcellera Biologics Inc a strong buy (8 buy, 1 hold, 0 sell out of 9) with an average price target of $10.50.
| Fund | Stake |
|---|---|
| Baker Bros Advisors LP | 9.91% |
| Capital World Investors | 4.38% |
| Two Sigma Investments LLC | 3.46% |
| TD Waterhouse Canada Inc | 3.13% |
| UBS Asset Mgmt Americas Inc | 2.48% |
| UBS Group AG | 1.38% |
| ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 1.34% |
| BlackRock Inc | 1.32% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 | 2026-07-29 |
| Board / officer change · Q2 2026 | 2026-07-06 |
| Company announcement · Q2 2026 | 2026-06-17 |
| Shareholder vote results · Q2 2026 | 2026-06-12 |
| Quarterly report · Q1 2026 | 2026-05-11 |
| Proxy statement · Q4 2025 | 2026-04-29 |
| Annual report FY2025 | 2026-02-24 |
| Quarterly report · Q3 2025 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Abcellera Biologics Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.